Crispr Therapeutics Reports Positive Additional Phase 1 Data For Ctx310™ Targeting Angptl3 And Provides Update On In Vivo Cardiovascular Pipeline

Reuters
26 Jun
June 26 (Reuters) - CRISPR Therapeutics AG ::
*CRISPR THERAPEUTICS REPORTS POSITIVE ADDITIONAL PHASE 1 DATA FOR CTX310™ TARGETING ANGPTL3 AND PROVIDES UPDATE ON IN VIVO CARDIOVASCULAR PIPELINE
*CRISPR THERAPEUTICS AG - CTX310 SHOWS UP TO 82% TG AND 86% LDL REDUCTION
*CRISPR THERAPEUTICS AG - CTX320 DATA UPDATE EXPECTED IN H1 2026
*CRISPR THERAPEUTICS AG - COMPLETE PHASE 1 DATA FOR CTX310 EXPECTED IN H2 2025

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 26-JUN-202511:00:00.217 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10